Dare Bioscience, Inc. financial data

Symbol
DARE on Nasdaq
Industry
Pharmaceutical Preparations
Location
3655 Nobel Drive, Suite 260, San Diego, CA
Fiscal year end
December 31
Former names
Cerulean Pharma Inc. (to 7/5/2017), Tempo Pharmaceuticals Inc (to 1/22/2008)
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 95.7 % +0.02%
Debt-to-equity -585 % +71.7%
Return On Equity 102 % -95.7%
Return On Assets -21.1 % +82.5%
Operating Margin -1.24K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8.85M shares -91.2%
Common Stock, Shares, Outstanding 8.7M shares +4.43%
Entity Public Float 34M USD -56.1%
Common Stock, Value, Issued 870 USD +4.44%
Weighted Average Number of Shares Outstanding, Basic 8.5M shares +16.8%
Weighted Average Number of Shares Outstanding, Diluted 8.5M shares +16.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.88M USD -95.8%
Revenue from Contract with Customer, Excluding Assessed Tax 2.84M USD
Research and Development Expense 14.2M USD -34%
General and Administrative Expense 9.16M USD -24.4%
Operating Income (Loss) -23.5M USD +24.2%
Net Income (Loss) Attributable to Parent -4.05M USD +86.6%
Earnings Per Share, Basic -0.48 USD/shares +88.4%
Earnings Per Share, Diluted -0.48 USD/shares +88.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 15.7M USD +49.8%
Other Assets, Current 152K USD -24.4%
Assets, Current 18.4M USD +5.16%
Property, Plant and Equipment, Net 1.34M USD +104%
Operating Lease, Right-of-Use Asset 1.21M USD -8.54%
Other Assets, Noncurrent 1.1M USD +83.2%
Assets 22.1M USD +3.85%
Accounts Payable, Current 1.46M USD -57%
Employee-related Liabilities, Current 806K USD +0.03%
Accrued Liabilities, Current 3.04M USD +5.33%
Contract with Customer, Liability, Current 205K USD
Liabilities, Current 21.6M USD +5.51%
Contract with Customer, Liability, Noncurrent 1M USD 0%
Operating Lease, Liability, Noncurrent 754K USD -19.4%
Liabilities 28.1M USD +6.77%
Accumulated Other Comprehensive Income (Loss), Net of Tax -429K USD -18.8%
Retained Earnings (Accumulated Deficit) -175M USD -2.37%
Stockholders' Equity Attributable to Parent -6.01M USD -19.1%
Liabilities and Equity 22.1M USD +3.85%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.81M USD +57.7%
Net Cash Provided by (Used in) Financing Activities 14K USD -98.9%
Net Cash Provided by (Used in) Investing Activities -7.3K USD
Common Stock, Shares Authorized 240M shares 0%
Common Stock, Shares, Issued 8.7M shares +4.43%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.85M USD +53.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 16M USD +48%
Deferred Tax Assets, Valuation Allowance 115M USD +2.13%
Deferred Tax Assets, Gross 115M USD +2.13%
Operating Lease, Liability 1.3M USD -7.26%
Depreciation 10.8K USD +13.4%
Payments to Acquire Property, Plant, and Equipment 7.3K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -4.12M USD +86.3%
Lessee, Operating Lease, Liability, to be Paid 1.47M USD -10%
Property, Plant and Equipment, Gross 1.51M USD +88.6%
Operating Lease, Liability, Current 549K USD +17%
Lessee, Operating Lease, Liability, to be Paid, Year Two 680K USD +32.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 660K USD +11.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 167K USD -27.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 130K USD -75.4%
Deferred Tax Assets, Operating Loss Carryforwards 86.6M USD +0.47%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 2.82M USD +7.91%
Operating Lease, Payments 600K USD +50%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%